[go: up one dir, main page]

FI946064L - Apuaineita sisältävä rokotekoostumus - Google Patents

Apuaineita sisältävä rokotekoostumus Download PDF

Info

Publication number
FI946064L
FI946064L FI946064A FI946064A FI946064L FI 946064 L FI946064 L FI 946064L FI 946064 A FI946064 A FI 946064A FI 946064 A FI946064 A FI 946064A FI 946064 L FI946064 L FI 946064L
Authority
FI
Finland
Prior art keywords
composition containing
vaccine composition
containing adjuvants
adjuvants
vaccine
Prior art date
Application number
FI946064A
Other languages
English (en)
Swedish (sv)
Other versions
FI946064A0 (fi
FI109767B (fi
Inventor
Jean-Paul Prieels
Nathalie Marie- Garcon-Johnson
Moncef Slaoui
Pietro Pala
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9213559A external-priority patent/GB9213559D0/en
Priority claimed from GB929226283A external-priority patent/GB9226283D0/en
Priority claimed from GB939304056A external-priority patent/GB9304056D0/en
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of FI946064A0 publication Critical patent/FI946064A0/fi
Publication of FI946064L publication Critical patent/FI946064L/fi
Application granted granted Critical
Publication of FI109767B publication Critical patent/FI109767B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
FI946064A 1992-06-25 1994-12-23 Menetelmä rokotekoostumuksen valmistamikseksi FI109767B (fi)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB9213559A GB9213559D0 (en) 1992-06-25 1992-06-25 Vaccines
GB9213559 1992-06-25
GB929226283A GB9226283D0 (en) 1992-12-17 1992-12-17 Vaccines
GB9226283 1992-12-17
GB939304056A GB9304056D0 (en) 1993-03-01 1993-03-01 Vaccines
GB9304056 1993-03-01
PCT/EP1993/001524 WO1994000153A1 (en) 1992-06-25 1993-06-15 Vaccine composition containing adjuvants
EP9301524 1993-06-15

Publications (3)

Publication Number Publication Date
FI946064A0 FI946064A0 (fi) 1994-12-23
FI946064L true FI946064L (fi) 1995-02-22
FI109767B FI109767B (fi) 2002-10-15

Family

ID=27266263

Family Applications (1)

Application Number Title Priority Date Filing Date
FI946064A FI109767B (fi) 1992-06-25 1994-12-23 Menetelmä rokotekoostumuksen valmistamikseksi

Country Status (31)

Country Link
US (2) US5750110A (fi)
EP (2) EP0761231B1 (fi)
JP (1) JP3755890B2 (fi)
KR (1) KR100278157B1 (fi)
CN (1) CN1122530C (fi)
AP (1) AP408A (fi)
AT (2) ATE188613T1 (fi)
AU (1) AU661404B2 (fi)
CA (1) CA2138997C (fi)
CZ (1) CZ282235B6 (fi)
DE (2) DE69313134T2 (fi)
DK (2) DK0761231T3 (fi)
ES (2) ES2108278T3 (fi)
FI (1) FI109767B (fi)
GR (2) GR3025184T3 (fi)
HK (2) HK1022074A1 (fi)
HU (1) HU219808B (fi)
IL (1) IL106109A (fi)
MA (1) MA22911A1 (fi)
MX (1) MX9303773A (fi)
MY (1) MY109278A (fi)
NO (1) NO317546B1 (fi)
NZ (1) NZ253137A (fi)
PL (1) PL170980B1 (fi)
PT (1) PT761231E (fi)
RU (1) RU2118164C1 (fi)
SG (2) SG90042A1 (fi)
SI (1) SI9300335B (fi)
SK (1) SK279188B6 (fi)
UA (1) UA40597C2 (fi)
WO (1) WO1994000153A1 (fi)

Families Citing this family (480)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
EP0761231B1 (en) * 1992-06-25 2000-01-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
CA2156525A1 (en) * 1993-02-19 1994-09-01 Susan Dillon Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
US5773011A (en) * 1993-09-27 1998-06-30 Gerbu Biotechnik Gmbh Method of preparing a synergistic immunological adjuvant formulation
US6083513A (en) * 1993-11-16 2000-07-04 Gerbu Biotechnik Gmbh Method for increasing the yield of antibodies in the techniques of immunology
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AUPM446594A0 (en) * 1994-03-16 1994-04-14 Csl Limited Cytotoxic t-cell epitopes identified within epstein-barr virus
GB9506863D0 (en) * 1995-04-03 1995-05-24 Smithkline Beecham Biolog Vaccines
US20010053365A1 (en) * 1995-04-25 2001-12-20 Smithkline Beecham Biologicals S.A. Vaccines
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6846489B1 (en) * 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
GB9513261D0 (en) * 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
GB2324093A (en) 1996-01-04 1998-10-14 Rican Limited Helicobacter pylori bacterioferritin
US7112331B2 (en) 1996-02-09 2006-09-26 Smithkline Beecham Biologicals, S.A. Vaccines against varicella zoster virus gene 63 product
GB9616351D0 (en) * 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
GB9706957D0 (en) * 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
BR9809149A (pt) * 1997-05-20 2000-08-01 Galenica Pharmaceuticals Inc Análogos de triterpeno saponina dotados de adjuvante e atividade imonoestimulatória
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
GB9712347D0 (en) * 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
US7459524B1 (en) * 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
GB9724531D0 (en) 1997-11-19 1998-01-21 Smithkline Biolog Novel compounds
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
DK1659178T3 (da) 1998-02-05 2010-07-12 Glaxosmithkline Biolog Sa Fremgangsmåde til oprensning eller fremstilling af et MAGE-protein
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
EP1068329A2 (en) 1998-04-07 2001-01-17 Corixa Corporation FUSION PROTEINS OF $i(MYCOBACTERIUM TUBERCULOSIS) ANTIGENS AND THEIR USES
GB9808866D0 (en) 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
CA2325055A1 (en) * 1998-04-29 1999-11-04 American Cyanamid Company Vaccines containing recombinant pilin against neisseria gonorrhoeae or neisseria meningitidis
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
AU5467899A (en) 1998-08-07 2000-02-28 University Of Washington Immunological herpes simplex virus antigens and methods for use thereof
WO2000009075A2 (en) 1998-08-14 2000-02-24 Galenica Pharmaceuticals, Inc. Chemically modified saponins and the use thereof as adjuvants
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
KR100629028B1 (ko) * 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
GB9826886D0 (en) * 1998-12-07 1999-01-27 Smithkline Beecham Biolog Novel compounds
US20020061848A1 (en) * 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
ATE527360T1 (de) 1998-12-08 2011-10-15 Glaxosmithkline Biolog Sa Neue verbindungen abgeleitet von neisseria meningitidis
HUP0400719A3 (en) 1998-12-08 2010-08-30 Corixa Corp Compounds and methods for treatment and diagnosis of chlamydial infection
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US7666988B1 (en) 1999-03-12 2010-02-23 Glaxosmithkline Biologicals S.A. BASB082 Polypeptides
GB9909077D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
CZ303653B6 (cs) 1999-03-19 2013-01-30 Smithkline Beecham Biologicals S. A. Imunogenní prostredek
EP1169347B1 (en) 1999-04-02 2008-07-02 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
JP2002542203A (ja) 1999-04-19 2002-12-10 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9919468D0 (en) 1999-08-17 1999-10-20 Smithkline Beecham Biolog Vaccine
EP1964573B1 (en) 1999-10-22 2014-11-26 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
US20030158134A1 (en) * 2000-01-31 2003-08-21 Gerald Voss Vaccine for the prophylactic or therapeutic immunization against hiv
BR0108654A (pt) 2000-02-23 2003-04-29 Smithkline Beecham Biolog Composição imunogênica, polipeptìdeo isolado, vetor de expressão ou um microorganismo vivo recombinante, célula hospedeira, processos para produzir uma composição imunogênica e um polipeptìdeo ou um fragmento imunogênico do mesmo, uso de um polipeptìdeo ou de um polinucleotìdeo que codifica um polipeptìdeo, método para o tratamento de um indivìduo pela imunoprofilaxia ou terapia, anticorpo, agonista ou antagonista ao polipeptìdeo, composto, e, processos para diagnosticar, uma doença ou uma suscetibilidade a uma doença e a presença de câncer colorretal ou uma suscetibilidade ao câncer colorretal, em um indivìduo
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US6919187B2 (en) * 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
DE60133190T2 (de) 2000-04-21 2009-04-02 CORIXA CORP., Wilmington Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
AU5810201A (en) 2000-05-10 2001-11-20 Aventis Pasteur Immunogenic polypeptides encoded by mage minigenes and uses thereof
WO2001098460A2 (en) 2000-06-20 2001-12-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
AR029540A1 (es) 2000-06-28 2003-07-02 Corixa Corp COMPOSICIONES Y METODOS PARA EL DIAGNoSTICO Y LA TERAPIA DE CA NCER DE PULMoN
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
PT1946769E (pt) 2000-06-29 2012-06-27 Smithkline Beecham Biolog Composição de vacina multivalente com dose reduzida de haemophilus influenzae de tipo b
UA79735C2 (uk) 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
KR100831139B1 (ko) 2000-10-18 2008-05-20 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
EP1201250A1 (en) * 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogenic compositions comprising liver stage malarial antigens
EP1671981A3 (en) 2000-10-27 2006-07-05 Chiron SRL. Nucleic acids and proteins from streptococcus group A
US6892140B1 (en) 2000-11-27 2005-05-10 Enteron, Inc. Immunogenic cancer peptides and uses thereof
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
EP2339035A1 (en) 2000-12-07 2011-06-29 Novartis Vaccines and Diagnostics, Inc. Endogenous retroviruses up-regulated in prostate cancer
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
ATE503493T1 (de) 2001-02-23 2011-04-15 Glaxosmithkline Biolog Sa Influenza vakzinzusammensetzungen zur intradermaler verabreichung
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
US20020193295A1 (en) * 2001-05-04 2002-12-19 Emanuel Calenoff Immunogenic peptides and uses thereof
JP2005504513A (ja) 2001-05-09 2005-02-17 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
US20100221284A1 (en) 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
EP2241309A3 (en) 2001-07-10 2012-12-26 Corixa Corporation Methods for encapsulation of proteins and adjuants in microspheres
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0118367D0 (en) 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
CA2476755C (en) 2001-12-17 2014-08-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
US7030094B2 (en) * 2002-02-04 2006-04-18 Corixa Corporation Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and QS-21
EP2572707A3 (en) 2002-02-20 2013-11-06 Novartis Vaccines and Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
US7351413B2 (en) 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
MXPA04010255A (es) 2002-04-19 2008-03-04 Univ Toronto Metodos inmunologicos y composiciones para el tratamiento de la enfermedad de alzheimier.
EP1532161B1 (en) 2002-06-13 2012-02-15 Novartis Vaccines and Diagnostics, Inc. Vectors for expression of hml-2 polypeptides
DE60335755D1 (de) 2002-07-18 2011-02-24 Univ Washington Pharmazeutische Zusammensetzungen, die immunologisch aktive Herpes simplex Virus Proteinfragmente enthalten
PL220107B1 (pl) 2002-08-02 2015-08-31 Glaxosmithkline Biolog Sa Preparat immunogenny, szczepionka oraz zastosowanie tej szczepionki
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
ES2608048T3 (es) 2002-10-11 2017-04-05 Glaxosmithkline Biologicals Sa Vacunas polipeptídicas para protección amplia contra linajes meningocócicos hipervirulentos
CA2502268A1 (en) 2002-10-23 2004-05-06 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
DE60332477D1 (de) 2002-11-15 2010-06-17 Novartis Vaccines & Diagnostic Unerwartete oberflächenproteine in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
ES2309485T3 (es) 2003-01-06 2008-12-16 Wyeth Composiciones y procedimientos para diagnosticar y tratar los canceres de colon.
CN102319427A (zh) 2003-01-30 2012-01-18 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
PT1631264E (pt) 2003-06-02 2009-11-03 Novartis Vaccines & Diagnostic Composições imunogénicas à base de micropartículas biodegradáveis que compreendem um toxóide de difteria e do tétano
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
SG147465A1 (en) 2003-09-02 2008-11-28 Glaxosmithkline Biolog Sa Vaccine
ES2397923T3 (es) 2003-10-02 2013-03-12 Novartis Ag Vacunas líquidas para múltiples serogrupos meningocócicos
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
ES2346314T3 (es) 2003-10-02 2010-10-14 Glaxosmithkline Biolog Sa Antigenos de b. pertussis y uso de los mismos en vacunacion.
GB0323965D0 (en) * 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
EP1708745B1 (en) 2003-12-23 2012-04-18 Arbor Vita Corporation Antibodies for oncogenic strains of hpv and methods of their use
CA2555274A1 (en) 2004-02-05 2005-08-25 The Ohio State University Research Foundation Chimeric vegf peptides
EP1722815A1 (en) 2004-03-09 2006-11-22 Chiron Corporation Influenza virus vaccines
BRPI0510315A (pt) 2004-04-30 2007-10-16 Chiron Srl integração de vacinação com conjugado meningocócico
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
GB0411411D0 (en) * 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
EP2811027A1 (en) 2004-05-21 2014-12-10 Novartis Vaccines and Diagnostics, Inc. Alphavirus vectors for RSV and PIV vaccines
WO2006031264A2 (en) 2004-05-25 2006-03-23 Oregon Health And Science University Siv and hiv vaccination using rhcmv- and hcmv-based vaccine vectors
AU2005249212B2 (en) 2004-05-28 2010-05-20 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
WO2006078318A2 (en) 2004-07-29 2006-07-27 Novartis Vaccines And Diagnostics Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
GB0420634D0 (en) * 2004-09-16 2004-10-20 Glaxosmithkline Biolog Sa Vaccines
WO2006032475A2 (en) 2004-09-22 2006-03-30 Glaxosmithkline Biologicals S.A. Staphylococcal immunogenic compositions
CA2587084C (en) 2004-10-08 2019-07-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Modulation of replicative fitness by using less frequently used synonym ous codons
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
ES2396555T3 (es) 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
EP1838348B1 (en) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanized amyloid beta antibodies for use in improving cognition
PT2682126T (pt) 2005-01-27 2017-02-28 Children`S Hospital & Res Center At Oakland Vacinas de vesícula com base em agn1870 para proteção de amplo espetro contra doenças causadas por neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
CN101203529A (zh) 2005-02-18 2008-06-18 诺华疫苗和诊断公司 来自脑膜炎/脓毒症相关性大肠杆菌的蛋白质和核酸
SI1858920T1 (sl) 2005-02-18 2016-07-29 Glaxosmithkline Biologicals S.A. Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
CN103372206A (zh) 2005-03-31 2013-10-30 葛兰素史密丝克莱恩生物有限公司 针对衣原体感染的疫苗
EP2426141B1 (en) 2005-04-29 2014-10-01 GlaxoSmithKline Biologicals S.A. Method for preventing or treating M tuberculosis infection
AU2006261342B2 (en) 2005-06-15 2012-02-02 The Ohio State University Research Foundation Her-2 peptides
GB0513421D0 (en) * 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
EP1910410B1 (en) 2005-07-01 2011-10-26 Forsyth Dental Infirmary for Children Tuberculosis antigen detection assays and vaccines
CA2626253A1 (en) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
US10842867B2 (en) 2005-11-04 2020-11-24 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
DE06808434T1 (de) * 2005-11-04 2009-12-17 Novartis Vaccines And Diagnostics S.R.L. Emulsionen mit freiem wässrigen phasen tensid als adjuvans für spalt-grippeimpfstoffe
CA2628206A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
JP2009514839A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル サイトカイン誘導剤を含むアジュバントインフルエンザワクチン
EP2360175B1 (en) 2005-11-22 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Norovirus and Sapovirus virus-like particles (VLPs)
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
TR201900418T4 (tr) 2005-12-22 2019-02-21 Glaxosmithkline Biologicals Sa Pnömokok polisakkarit konjugat aşısı.
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
JP2009522011A (ja) 2005-12-30 2009-06-11 Ｔｔｉ・エルビュー株式会社 活性物質を生体界面に送達するイオントフォレーシスシステム、装置及び方法
EP1981905B1 (en) 2006-01-16 2016-08-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Chlamydia vaccine
CN101374859B (zh) 2006-01-17 2014-11-26 阿恩·福斯格伦 新的表面外露流感嗜血菌蛋白质(蛋白质E；pE)
KR20080089663A (ko) 2006-01-27 2008-10-07 노바티스 백신즈 앤드 다이아그노스틱스 게엠베하 운트 콤파니 카게 적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신
EP2357184B1 (en) 2006-03-23 2015-02-25 Novartis AG Imidazoquinoxaline compounds as immunomodulators
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
JP2009534303A (ja) 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
US20100021503A1 (en) 2006-03-30 2010-01-28 Glaxosmithkline Biologicals S.A. Immunogenic composition
BRPI0710023A2 (pt) 2006-03-30 2011-08-02 Embrex Inc métodos e composições para a vacinação de aves domésticas
US9839685B2 (en) 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
EP2258874B1 (en) 2006-06-02 2015-03-18 GlaxoSmithKline Biologicals S.A. Method for identifying whether a patient will be responder or not to immunotherapy
WO2009030978A2 (en) 2006-06-09 2009-03-12 Novartis Ag Conformers of bacterial adhesins
JP5275982B2 (ja) 2006-06-12 2013-08-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
AU2007276219B2 (en) 2006-07-18 2013-10-03 Glaxosmithkline Biologicals S.A. Vaccines for malaria
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
US8323664B2 (en) 2006-07-25 2012-12-04 The Secretary Of State For Defence Live vaccine strains of Francisella
EP2064230A2 (en) 2006-08-16 2009-06-03 Novartis AG Immunogens from uropathogenic escherichia coli
WO2008091398A2 (en) * 2006-08-31 2008-07-31 Baylor Research Institute Jc virus vaccine
CN103585624A (zh) 2006-09-07 2014-02-19 葛兰素史密丝克莱恩生物有限公司 疫苗
EP3456348B1 (en) 2006-09-11 2025-03-26 Seqirus UK Limited Making influenza virus vaccines without using eggs
DK2468300T3 (da) 2006-09-26 2018-01-29 Infectious Disease Res Inst Vaccinesammensætning indeholdende syntetisk adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20110045022A1 (en) 2006-12-06 2011-02-24 Theodore Tsai Vaccines including antigen from four strains of influenza virus
CN103550764A (zh) 2007-03-02 2014-02-05 葛兰素史密丝克莱恩生物有限公司 疫苗组合物及其在刺激免疫反应中的用途
MX351247B (es) 2007-04-04 2017-10-05 Infectious Disease Res Institute Star Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
AU2008248640A1 (en) 2007-05-02 2008-11-13 Glaxosmithkline Biologicals S.A. Vaccine
KR101579947B1 (ko) 2007-06-26 2015-12-28 글락소스미스클라인 바이오로지칼즈 에스.에이. 스트렙토코쿠스 뉴모니애 캡슐 다당류 컨쥬게이트를 포함하는 백신
DK2185191T3 (da) 2007-06-27 2012-12-03 Novartis Ag Influenzavacciner med lavt indhold af tilsætningsstoffer
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
SI2182983T1 (sl) 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
KR101580660B1 (ko) * 2007-08-02 2015-12-28 바이오앤드백스 파마슈티칼즈, 리미티드. 다중체 다중-에피토프 인플루엔자 백신
JP2010535504A (ja) 2007-08-03 2010-11-25 プレジデント アンド フェロウズ オブ ハーバード カレッジ クラミジア抗原
UY31285A1 (es) 2007-08-13 2009-03-31 Vacunas
AU2008299376B2 (en) 2007-09-12 2013-02-28 Glaxosmithkline Biologicals S.A. GAS57 mutant antigens and GAS57 antibodies
MX2010002965A (es) 2007-09-17 2010-09-14 Oncomethylome Sciences Sa Deteccion mejorada de la expresion de mage-a.
EP2045263A1 (en) 2007-10-02 2009-04-08 Universite Libre De Bruxelles Identification and molecular characterisation of salivary metalloproteases expressed in the tick salivary glands
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
AU2008331800A1 (en) 2007-12-03 2009-06-11 President And Fellows Of Harvard College Chlamydia antigens
EP2227483B1 (en) 2007-12-19 2017-04-19 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Soluble forms of hendra and nipah virus f glycoprotein and uses thereof
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
PT2235046E (pt) 2007-12-21 2012-10-26 Novartis Ag Formas mutantes de estreptolisina o
LT2222710T (lt) * 2007-12-24 2016-12-12 Id Biomedical Corporation Of Quebec Rekombinantiniai rsv antigenai
EP3263591B1 (en) 2008-02-21 2019-03-27 GlaxoSmithKline Biologicals S.A. Meningococcal fhbp polypeptides
US9511131B2 (en) 2008-03-10 2016-12-06 Children's Hospital & Research Center Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
WO2009127666A2 (en) * 2008-04-15 2009-10-22 Glaxosmithkline Biologicals S.A. Method and compositions
JP2011518186A (ja) 2008-04-18 2011-06-23 ザ ジェネラル ホスピタル コーポレイション 自己集合性ワクチンを使用する免疫療法
CA2826508C (en) 2008-05-23 2016-07-19 The Regents Of The University Of Michigan Nanoemulsion vaccines
BRPI0915960A2 (pt) * 2008-07-18 2019-09-24 Id Biomedical Corp antígenos de polipeptídeos do vírus sincicial respiratório qimérico
KR20110060891A (ko) 2008-07-25 2011-06-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 신규한 조성물 및 방법
CA2731547C (en) 2008-07-25 2019-04-30 Glaxo Group Limited The tuberculosis rv2386c protein, compositions and uses thereof
KR101707569B1 (ko) 2008-08-01 2017-02-16 감마 백신즈 피티와이 리미티드 인플루엔자 백신
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
WO2010036938A2 (en) 2008-09-26 2010-04-01 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US9974844B2 (en) 2008-11-17 2018-05-22 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
EP2356225A1 (en) 2008-12-03 2011-08-17 Protea Vaccine Technologies Ltd. GLUTAMYL tRNA SYNTHETASE (GtS) FRAGMENTS
EP2865389A1 (en) 2008-12-09 2015-04-29 Pfizer Vaccines LLC IgE CH3 peptide vaccine
US8465751B2 (en) 2009-01-12 2013-06-18 Novartis Ag Cna—B domain antigens in vaccines against gram positive bacteria
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
US20100234283A1 (en) 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
US8460674B2 (en) 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
AU2010212550B2 (en) 2009-02-10 2016-03-10 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
EP2403526B1 (en) 2009-03-06 2019-05-15 GlaxoSmithKline Biologicals SA Chlamydia antigens
EP2408933A2 (en) 2009-03-17 2012-01-25 MDxHealth SA Improved detection of gene expression
WO2010115172A2 (en) 2009-04-03 2010-10-07 University Of Washington Antigenic peptide of hsv-2 and methods for using same
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
EP2419129A2 (en) 2009-04-14 2012-02-22 Novartis AG Compositions for immunising against staphylococcus aerus
MX340830B (es) 2009-04-30 2016-07-26 Coley Pharm Group Inc Vacuna neumococica y usos de la misma.
US8668911B2 (en) 2009-05-14 2014-03-11 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
TWI494125B (zh) 2009-06-05 2015-08-01 Infectious Disease Res Inst 合成的葡萄吡喃糖基脂質佐劑
CN102802665B (zh) 2009-06-15 2015-11-25 新加坡国立大学 流感疫苗、组合物及使用方法
CN102596243B (zh) 2009-06-16 2015-10-21 密执安大学评议会 纳米乳剂疫苗
MX2012000035A (es) 2009-06-24 2012-02-28 Id Biomedical Corp Quebec Antigenos de virus de sincicio respiratorio recombinantes.
MX2012000036A (es) 2009-06-24 2012-02-28 Glaxosmithkline Biolog Sa Vacuna.
ES2662716T3 (es) 2009-07-07 2018-04-09 Glaxosmithkline Biologicals Sa Inmunógenos conservados de Escherichia coli
AR077757A1 (es) 2009-07-15 2011-09-21 Novartis Ag Composiciones de proteinas de fusion del virus sincicial respiratorio (rsv) y metodos para su preparacion
SG178035A1 (en) 2009-07-16 2012-03-29 Novartis Ag Detoxified escherichia coli immunogens
WO2011013034A1 (en) 2009-07-30 2011-02-03 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
JP5933437B2 (ja) * 2009-08-26 2016-06-08 セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． Ｔ細胞ヘルプを誘発する組成物
ES2562259T3 (es) 2009-08-27 2016-03-03 Glaxosmithkline Biologicals Sa Polipéptidos híbridos que incluyen secuencias fHBP meningocócicas
CN104548089B (zh) 2009-09-03 2017-09-26 辉瑞疫苗有限责任公司 Pcsk9疫苗
AU2010293902A1 (en) 2009-09-10 2012-03-22 Novartis Ag Combination vaccines against respiratory tract diseases
GB0917457D0 (en) 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
US20130022639A1 (en) 2009-09-30 2013-01-24 Novartis Ag Expression of meningococcal fhbp polypeptides
BR112012009014B8 (pt) 2009-09-30 2022-10-04 Novartis Ag Processo para preparar conjugado de polissacarídeo capsular de s. aureus tipo 5 ou tipo 8 e molécula de transporte crm197, conjugado e composição imunogênica
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
AU2010310985B2 (en) 2009-10-27 2014-11-06 Glaxosmithkline Biologicals S.A. Modified meningococcal fHBP polypeptides
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
SG10201408505SA (en) 2009-12-22 2015-02-27 Celldex Therapeutics Inc Vaccine compositions
EP2519265B1 (en) 2009-12-30 2018-11-14 GlaxoSmithKline Biologicals SA Polysaccharide immunogens conjugated to e. coli carrier proteins
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
JP2013521326A (ja) 2010-03-10 2013-06-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
ES2625406T3 (es) 2010-03-25 2017-07-19 Oregon Health & Science University Glicoproteínas de CMV y vectores recombinantes
CN103221065A (zh) 2010-03-26 2013-07-24 葛兰素史密斯克莱生物公司 Hiv疫苗
BR122021020829B8 (pt) 2010-03-30 2022-12-27 Children´S Hospital & Res Center At Oakland Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
JP2013529894A (ja) 2010-04-07 2013-07-25 ノバルティス アーゲー パルボウイルスｂ１９のウイルス様粒子を生成するための方法
BR112012029912A2 (pt) 2010-05-26 2016-11-16 Selecta Biosciences Inc vácinas de combinação de nanotransportadores sintéticos
EP2575988A1 (en) 2010-05-28 2013-04-10 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
KR101609032B1 (ko) 2010-06-04 2016-04-04 와이어쓰 엘엘씨 스트렙토코커스 뉴모니아 백신 제제
US8895017B2 (en) 2010-06-07 2014-11-25 Pfizer Inc. HER-2 peptides and vaccines
EP2575868A1 (en) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
AU2011276328C1 (en) 2010-07-06 2016-01-21 Novartis Ag Norovirus derived immunogenic compositions and methods
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2012041669A1 (en) 2010-09-27 2012-04-05 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
EA201390452A1 (ru) 2010-09-27 2013-11-29 Глаксосмитклайн Байолоджикалс С.А. Вакцина
GB201017519D0 (en) 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
US20130345079A1 (en) 2010-10-27 2013-12-26 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
GB201101331D0 (en) 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
ES2859673T3 (es) 2010-11-08 2021-10-04 Infectious Disease Res Inst Vacunas que comprenden polipéptidos de nucleósido hidrolasa no específica y esterol 24-c-metiltransferasa (SMT) para el tratamiento y el diagnóstico de la leishmaniasis
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
NZ611176A (en) 2010-12-02 2015-07-31 Bionor Immuno As Peptide scaffold design
US20130315959A1 (en) 2010-12-24 2013-11-28 Novartis Ag Compounds
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
BR112013017488A2 (pt) 2011-01-06 2017-08-01 Bionor Immuno As peptídeos imunogênicos multiméricos e monoméricos
US10342862B2 (en) 2011-01-26 2019-07-09 Glaxosmithkline Biologicals, Sa RSV immunization regimen
AU2012211043B2 (en) 2011-01-27 2017-04-06 Gamma Vaccines Pty Limited Combination vaccines
CA2828068C (en) 2011-02-22 2019-03-19 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
WO2012135177A2 (en) 2011-03-29 2012-10-04 Uab Research Foundation Methods and compositions for cytomegalovirus il-10 protein
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
SG194083A1 (en) 2011-04-08 2013-11-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
LT2707385T (lt) 2011-05-13 2017-12-11 Glaxosmithkline Biologicals Sa Iš anksto sulieti rsv f antigenai
US20130156803A1 (en) 2011-06-04 2013-06-20 Rochester General Hospital Research Institute Compositions and methods related to p6
PL2691530T3 (pl) 2011-06-10 2019-02-28 Oregon Health & Science University Glikoproteiny i rekombinowane wektory CMV
MX2013013627A (es) 2011-06-21 2014-04-25 Oncofactor Corp Composiciones y metodos para la terapia y diagnostico de cancer.
US10030052B2 (en) 2011-07-25 2018-07-24 Glaxosmithkline Biologicals Sa Parvovirus Vp1 unique region polypeptides and compositions thereof
JP2014521687A (ja) 2011-07-29 2014-08-28 セレクタ バイオサイエンシーズ インコーポレーテッド 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
GB201114919D0 (en) 2011-08-30 2011-10-12 Glaxosmithkline Biolog Sa Method
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
US20150190501A1 (en) 2011-09-12 2015-07-09 Imperial Innovations Limited Methods and compositions for raising an immune response to hiv
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
WO2013038375A2 (en) 2011-09-14 2013-03-21 Novartis Ag Methods for making saccharide-protein glycoconjugates
JP2014531442A (ja) 2011-09-14 2014-11-27 ノバルティス アーゲー Ｅｓｃｈｅｒｉｃｈｉａｃｏｌｉワクチンの組み合わせ
PE20141547A1 (es) 2011-09-16 2014-10-25 Ucb Pharma Sa Anticuerpos neutralizantes frente a las exotoxinas principales tcda y tcdb de clostridium difficile
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
CN103974718A (zh) 2011-12-08 2014-08-06 诺华股份有限公司 基于艰难梭菌毒素的疫苗
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
WO2013119856A1 (en) 2012-02-07 2013-08-15 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
JP2015509713A (ja) 2012-02-24 2015-04-02 ノバルティス アーゲー 線毛タンパク質および組成物
WO2013134577A2 (en) 2012-03-08 2013-09-12 Detectogen, Inc. Leishmaniasis antigen detection assays and vaccines
WO2013150518A1 (en) 2012-04-01 2013-10-10 Rappaport Family Institute For Research In The Medical Sciences Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
US9821050B2 (en) 2012-04-02 2017-11-21 The University Of North Carolina At Chapel Hill Chimeric dengue virus E glycoproteins comprising mutant domain I and domain II hinge regions
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
CA2871520C (en) 2012-04-26 2020-12-29 Novartis Ag Antigens from non-typeable h. influenzae
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659907A1 (en) * 2012-05-01 2013-11-06 Affiris AG Compositions
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
PE20142406A1 (es) 2012-05-04 2015-01-23 Pfizer Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna
JP6619648B2 (ja) 2012-05-16 2019-12-11 イミューン デザイン コーポレイション Ｈｓｖ−２のためのワクチン
KR20150021933A (ko) 2012-05-22 2015-03-03 노파르티스 아게 수막염구균 혈청군 x 포합체
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
AU2013273482A1 (en) 2012-06-06 2014-12-11 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
HUE065746T2 (hu) 2012-08-03 2024-06-28 Access To Advanced Health Inst Készítmények és eljárások aktív mycobacterium tuberculosis fertõzés kezelésére
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
US10232035B2 (en) 2012-09-14 2019-03-19 The Regents Of The University Of Colorado, A Body Corporate Conditionally replication deficient herpes virus and use thereof in vaccines
JP6283674B2 (ja) 2012-09-18 2018-02-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 外膜小胞
ES2672996T3 (es) 2012-10-02 2018-06-19 Glaxosmithkline Biologicals Sa Conjugados de sacáridos no lineales
AR092897A1 (es) 2012-10-03 2015-05-06 Novartis Ag Composiciones inmunogenicas
EP3859004A1 (en) 2012-10-24 2021-08-04 Platelet Targeted Therapeutics LLC Platelet targeted treatment
RS56886B1 (sr) 2012-11-30 2018-04-30 Glaxosmithkline Biologicals Sa Antigeni pseudomonasa i kombinacije antigena
TR201905272T4 (tr) 2012-12-05 2019-05-21 Glaxosmithkline Biologicals Sa İmmünojenik bileşim.
EP2978447B1 (en) 2013-03-28 2019-05-08 Infectious Disease Research Institute Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
SG11201508092YA (en) 2013-04-18 2015-10-29 Immune Design Corp Gla monotherapy for use in cancer treatment
EP3689375A1 (en) 2013-05-15 2020-08-05 The Governors Of The University Of Alberta E1e2 hcv vaccines and methods of use
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
ES2745431T3 (es) 2013-06-26 2020-03-02 Univ North Carolina Chapel Hill Composiciones para vacunas contra el virus del dengue y su uso
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
WO2015063611A2 (en) 2013-11-01 2015-05-07 University Of Oslo Albumin variants and uses thereof
US9993541B2 (en) 2013-11-13 2018-06-12 University Of Oslo Outer membrane vesicles and uses thereof
US11452767B2 (en) 2013-11-15 2022-09-27 Oslo Universitetssykehus Hf CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
WO2015103104A1 (en) 2014-01-06 2015-07-09 The United States Of America, As Represented By The Secretary Of Agriculture Attenuated salmonella enterica
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
DK3096785T3 (da) 2014-01-21 2020-09-21 Pfizer Immunogene sammensætninger omfattende konjugerede kapsel-saccharid-antigener og anvendelser deraf
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
TW201620927A (zh) 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途
SG11201607396WA (en) * 2014-03-25 2016-10-28 Government Of The Us Secretary Of The Army Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (mpla)-containing liposome composition and a saponin
LT3160500T (lt) 2014-06-25 2019-10-25 Glaxosmithkline Biologicals Sa Clostridium difficile imunogeninė kompozicija
TW201623329A (zh) 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
CN106715458A (zh) 2014-07-18 2017-05-24 华盛顿大学 癌症疫苗组合物及其使用方法
AR101256A1 (es) 2014-07-21 2016-12-07 Sanofi Pasteur Composición vacunal que comprende ipv y ciclodextrinas
BR112017001417B1 (pt) 2014-07-23 2023-11-07 Children's Hospital & Research Center At Oakland Variantes da proteína de ligação ao fator h (fhbp), composição imunogênica e uso de uma fhbp variante referência cruzada
US11083788B2 (en) 2014-10-10 2021-08-10 The Regents Of The University Of Michigan Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
BR112017008952A2 (pt) 2014-11-02 2018-01-16 Univ North Carolina Chapel Hill métodos e composições para vírus recombinantes da dengue para desenvolvimento de vacina e diagnóstico
US20170281744A1 (en) 2014-12-10 2017-10-05 Glaxosmithkline Biologicals Sa Method of treatment
SI3244917T1 (sl) 2015-01-15 2023-07-31 Pfizer Inc. Imunogenske kompozicije za uporabo v pnevmokoknih cepivih
WO2016134300A1 (en) 2015-02-20 2016-08-25 Board Of Regents, The University Of Texas System Methods and compositions for attenuated chlamydia as vaccine and vector
CN107249629A (zh) * 2015-02-26 2017-10-13 生控基因疫苗股份有限公司 包含免疫原性蛋白质及组合佐剂并用以诱发抗原特异性t细胞反应的疫苗组合物
WO2016141320A2 (en) 2015-03-05 2016-09-09 Northwestern University Non-neuroinvasive viruses and uses thereof
EP3270897A4 (en) 2015-03-20 2018-12-05 The Regents Of The University Of Michigan Immunogenic compositions for use in vaccination against bordetella
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3273989B1 (en) 2015-03-26 2023-12-27 Gpn Vaccines Pty Ltd Streptococcal vaccine
US10682314B2 (en) 2015-05-26 2020-06-16 Ohio State Innovation Foundation Nanoparticle based vaccine strategy against swine influenza virus
US10576131B2 (en) 2015-06-03 2020-03-03 Affiris Ag IL-23-p19 vaccines
EP3313439A2 (en) 2015-06-26 2018-05-02 Seqirus UK Limited Antigenically matched influenza vaccines
EP3319988A1 (en) 2015-07-07 2018-05-16 Affiris AG Vaccines for the treatment and prevention of ige mediated diseases
EP3325008A1 (en) 2015-07-21 2018-05-30 Pfizer Inc Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP3341017B1 (en) 2015-08-25 2024-10-16 Babita Agrawal Immunomodulatory compositions comprising caulobacter crescentus and use thereof
EP3359651A1 (en) 2015-10-05 2018-08-15 THE UNITED STATES OF AMERICA, represented by the S Human rota virus g9p[6]strain and use as a vaccine
JP7098519B2 (ja) 2015-10-08 2022-07-11 ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ Ｃ型肝炎ウイルスｅ１／ｅ２ヘテロダイマー及びそれを生成する方法
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
JP6884145B2 (ja) 2015-11-20 2021-06-09 ファイザー・インク 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
WO2017109698A1 (en) 2015-12-22 2017-06-29 Glaxosmithkline Biologicals Sa Immunogenic formulation
SI3405212T1 (sl) 2016-01-19 2020-09-30 Pfizer Inc. Cepiva proti raku
WO2017137085A1 (en) 2016-02-11 2017-08-17 Sanofi Pasteur Meningitidis vaccines comprising subtilinases
WO2017156461A2 (en) 2016-03-10 2017-09-14 Aperisys, Inc. Antigen-binding fusion proteins with modified hsp70 domains
EP3430039A1 (en) 2016-03-14 2019-01-23 Universitetet I Oslo Engineered immunoglobulins with altered fcrn binding
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
ES2929054T3 (es) 2016-05-16 2022-11-24 Access To Advanced Health Inst Formulación que contiene un agonista de TLR y métodos de uso
WO2017201390A1 (en) 2016-05-19 2017-11-23 The Regents Of The University Of Michigan Novel adjuvant compositions
MX2018014270A (es) 2016-05-21 2019-02-14 Infectious Disease Res Inst Composiciones y metodos para tratar la tuberculosis secundaria e infecciones po micobacteria no tuberculosa.
IL315825A (en) 2016-06-01 2024-11-01 Access To Advanced Health Inst Nanoalum particles containing a fixing factor
US11780924B2 (en) 2016-06-21 2023-10-10 University Of Oslo HLA binding vaccine moieties and uses thereof
CN109863169A (zh) 2016-08-23 2019-06-07 葛兰素史密丝克莱恩生物有限公司 具有连接至不变链(cd74)的短片段的抗原的融合肽
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
BR112019004913B1 (pt) 2016-09-16 2022-07-12 Infectious Disease Research Institute Vacinas que compreendem polipeptídeos de mycobacterium leprae para a prevenção, tratamento e diagnóstico de lepra
EP3518966A1 (en) 2016-09-29 2019-08-07 GlaxoSmithKline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
HUE059252T2 (hu) 2017-01-20 2022-11-28 Pfizer Immunogén készítmények pneumokokkusz vakcinákban történõ alkalmazásra
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
WO2018178264A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
WO2018201022A1 (en) * 2017-04-28 2018-11-01 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Compositions and methods for vaccine delivery
CN110996994A (zh) 2017-08-14 2020-04-10 葛兰素史密丝克莱恩生物有限公司 加强免疫应答的方法
US11123415B2 (en) 2017-08-16 2021-09-21 Ohio State Innovation Foundation Nanoparticle compositions for Salmonella vaccines
EP3678698A1 (en) 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules
US12005112B2 (en) 2017-09-07 2024-06-11 University Of Oslo Vaccine molecules
KR102755593B1 (ko) 2017-09-08 2025-01-20 액세스 투 어드밴스드 헬스 인스티튜트 사포닌을 포함하는 리포솜 제형 및 사용 방법
CA3075207A1 (en) 2017-09-13 2019-03-21 Sanofi Pasteur Human cytomegalovirus immunogenic composition
US11566050B2 (en) 2017-10-18 2023-01-31 The University Of North Carolina At Chapel Hill Methods and compositions for norovirus vaccines and diagnostics
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
WO2019173438A1 (en) 2018-03-06 2019-09-12 Stc. Unm Compositions and methods for reducing serum triglycerides
TW201946650A (zh) 2018-03-12 2019-12-16 美商詹森藥物公司 針對腹內感染之疫苗
JP2021526831A (ja) 2018-06-12 2021-10-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム アデノウイルスポリヌクレオチド及びポリペプチド
MX2021001479A (es) 2018-08-07 2021-04-28 Glaxosmithkline Biologicals Sa Novedosos procesos y vacunas.
EP3840770A1 (en) 2018-08-23 2021-06-30 GlaxoSmithKline Biologicals SA Immunogenic proteins and compositions
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
EP3851120A4 (en) 2018-09-11 2022-04-27 Shanghai Public Health Clinical Center Immunogen for broad-spectrum influenza vaccine and application thereof
CN113166733B (zh) 2018-11-16 2024-12-31 港大科桥有限公司 活减毒流感b病毒组合物及其制备和使用方法
EP3890775A1 (en) 2018-12-06 2021-10-13 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
WO2020121159A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
US20220184158A1 (en) 2018-12-21 2022-06-16 Glaxosmithkline Biologicals Sa Methods of inducing an immune response
GB201901608D0 (en) 2019-02-06 2019-03-27 Vib Vzw Vaccine adjuvant conjugates
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
EP3934687A1 (en) 2019-03-05 2022-01-12 GlaxoSmithKline Biologicals S.A. Hepatitis b immunisation regimen and compositions
EP3942028B9 (en) 2019-03-18 2023-08-23 Janssen Pharmaceuticals, Inc. Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof
TWI751513B (zh) 2019-03-18 2022-01-01 美商詹森藥物公司 E. coli O-抗原多醣生物結合物、其製備方法及其使用方法
WO2020208502A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
WO2020212461A1 (en) 2019-04-18 2020-10-22 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays
WO2021023691A1 (en) 2019-08-05 2021-02-11 Glaxosmithkline Biologicals Sa Immunogenic composition
EP4477230A2 (en) 2019-08-06 2024-12-18 The University of North Carolina at Chapel Hill Methods and compositions for stabilized recombinant flavivirus e protein dimers
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
EP3799884A1 (en) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
US20220362368A1 (en) 2019-10-02 2022-11-17 Janssen Vaccines & Prevention B.V. Staphylococcus peptides and methods of use
WO2021084429A1 (en) 2019-11-01 2021-05-06 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2021122551A1 (en) 2019-12-19 2021-06-24 Glaxosmithkline Biologicals Sa S. aureus antigens and compositions thereof
EP4090363B1 (en) 2020-01-16 2024-09-04 Janssen Pharmaceuticals, Inc. Fimh mutant, compositions therewith and use thereof
NL2027383B1 (en) 2020-01-24 2022-04-06 Aim Immunotech Inc Methods, compositions, and vaccines for treating a virus infection
WO2021160887A1 (en) 2020-02-14 2021-08-19 Immunor As Corona virus vaccine
BR112022015796A2 (pt) 2020-02-21 2022-10-11 Pfizer Purificação de sacarídeos
WO2021165928A2 (en) 2020-02-23 2021-08-26 Pfizer Inc. Escherichia coli compositions and methods thereof
JP2023514825A (ja) 2020-02-26 2023-04-11 ヴェルシテック リミテッド コロナウイルス感染症に対するｐｄ－１ベースのワクチン
WO2022029024A1 (en) 2020-08-03 2022-02-10 Glaxosmithkline Biologicals Sa Truncated fusobacterium nucleatum fusobacterium adhesin a (fada) protein and immunogenic compositios thereof
CN119454928A (zh) 2020-09-17 2025-02-18 杨森制药公司 多价疫苗组合物及其用途
US11225508B1 (en) 2020-09-23 2022-01-18 The University Of North Carolina At Chapel Hill Mouse-adapted SARS-CoV-2 viruses and methods of use thereof
WO2022083760A1 (zh) 2020-10-23 2022-04-28 江苏省疾病预防控制中心(江苏省公共卫生研究院) 融合蛋白及其应用
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
JP2023546615A (ja) 2020-10-27 2023-11-06 ファイザー・インク 大腸菌組成物およびその方法
MX2023005221A (es) 2020-11-04 2023-05-16 Pfizer Composiciones inmunogenicas para uso en vacunas neumococicas.
JP2023549736A (ja) 2020-11-10 2023-11-29 ファイザー・インク コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
WO2022147373A1 (en) 2020-12-31 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
EP4277921A1 (en) 2021-01-12 2023-11-22 Janssen Pharmaceuticals, Inc. Fimh mutants, compositions therewith and use thereof
US20220226465A1 (en) 2021-01-18 2022-07-21 ConserV Bioscience Coronavirus Immunogenic Compositions, Methods and Uses Thereof
CA3211240A1 (en) 2021-02-19 2022-08-25 Sanofi Pasteur Inc. Meningococcal b recombinant vaccine
WO2022175423A1 (en) 2021-02-22 2022-08-25 Glaxosmithkline Biologicals Sa Immunogenic composition, use and methods
JP2024514074A (ja) 2021-04-01 2024-03-28 ヤンセン ファーマシューティカルズ，インコーポレーテッド Ｅ．ｃｏｌｉ ｏ１８バイオコンジュゲートの産生
AU2022281543A1 (en) 2021-05-28 2023-11-23 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP4346893A2 (en) 2021-05-28 2024-04-10 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP4433080A1 (en) 2021-11-18 2024-09-25 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
CN118510548A (zh) 2022-01-13 2024-08-16 辉瑞公司 包含缀合的荚膜糖抗原的免疫原性组合物及其用途
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
KR20250008122A (ko) 2022-05-11 2025-01-14 화이자 인코포레이티드 보존제를 갖는 백신 제형의 제조 방법
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
US20240181028A1 (en) 2022-11-22 2024-06-06 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations
WO2024133160A1 (en) 2022-12-19 2024-06-27 Glaxosmithkline Biologicals Sa Hepatitis b compositions
WO2024160901A1 (en) 2023-02-02 2024-08-08 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024214016A1 (en) 2023-04-14 2024-10-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024241172A2 (en) 2023-05-19 2024-11-28 Glaxosmithkline Biologicals Sa Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
NZ209308A (en) 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
EP1088830A3 (en) 1987-06-22 2004-04-07 Medeva Holdings B.V. Hepatitis b surface antigen particles
DE3789866T2 (de) 1987-07-17 1994-09-22 Rhein Biotech Gesellschaft Fuer Neue Biotechnologische Prozesse Und Produkte Mbh, 40595 Duesseldorf DNA-Moleküle, die für FMDH-Kontrollabschnitte und Strukturgene für ein Protein mit FMDH-Aktivität kodieren, sowie deren Anwendung.
AU632493B2 (en) * 1988-05-03 1993-01-07 Lg Electronics Inc. Microprocessor having external control store
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DK0414374T3 (da) 1989-07-25 1998-03-09 Smithkline Beecham Biolog Hidtil ukendte antigener og fremgangsmåder til fremstilling deraf
JP3954643B2 (ja) 1991-11-16 2007-08-08 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム マラリア原虫由来のＣＳおよびＨＢｓＡＧ間のハイブリッド蛋白質
EP0761231B1 (en) * 1992-06-25 2000-01-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants

Also Published As

Publication number Publication date
AU4326393A (en) 1994-01-24
DE69327599D1 (de) 2000-02-17
KR950702125A (ko) 1995-06-19
JPH07508512A (ja) 1995-09-21
IL106109A (en) 1997-02-18
CZ282235B6 (cs) 1997-06-11
ATE188613T1 (de) 2000-01-15
EP0671948A1 (en) 1995-09-20
FI946064A0 (fi) 1994-12-23
ES2108278T3 (es) 1997-12-16
KR100278157B1 (ko) 2001-01-15
HU219808B (hu) 2001-08-28
SG90042A1 (en) 2002-07-23
CA2138997A1 (en) 1994-01-06
EP0761231B1 (en) 2000-01-12
FI109767B (fi) 2002-10-15
DK0761231T3 (da) 2000-05-08
MX9303773A (es) 1994-05-31
AP408A (en) 1995-09-27
DK0671948T3 (da) 1997-09-01
ATE156710T1 (de) 1997-08-15
SI9300335A (sl) 1993-12-31
UA40597C2 (uk) 2001-08-15
IL106109A0 (en) 1993-10-20
US7147862B1 (en) 2006-12-12
SG49909A1 (en) 1998-06-15
DE69327599T2 (de) 2000-08-10
SK159294A3 (en) 1995-08-09
HU9403778D0 (en) 1995-02-28
SI9300335B (sl) 2003-04-30
WO1994000153A1 (en) 1994-01-06
EP0671948B1 (en) 1997-08-13
CA2138997C (en) 2003-06-03
RU94046232A (ru) 1996-10-10
NO945003L (no) 1994-12-23
RU2118164C1 (ru) 1998-08-27
NZ253137A (en) 1996-08-27
JP3755890B2 (ja) 2006-03-15
GR3025184T3 (en) 1998-02-27
AU661404B2 (en) 1995-07-20
DE69313134D1 (de) 1997-09-18
PL170980B1 (pl) 1997-02-28
NO945003D0 (no) 1994-12-23
US5750110A (en) 1998-05-12
CN1122530C (zh) 2003-10-01
CZ329694A3 (en) 1995-08-16
GR3032742T3 (en) 2000-06-30
EP0761231A1 (en) 1997-03-12
HK1010097A1 (en) 1999-06-11
HK1022074A1 (en) 2000-07-21
MA22911A1 (fr) 1993-12-31
CN1086142A (zh) 1994-05-04
MY109278A (en) 1996-12-31
DE69313134T2 (de) 1998-02-26
PT761231E (pt) 2000-06-30
ES2143716T3 (es) 2000-05-16
AP9300541A0 (en) 1993-07-31
SK279188B6 (sk) 1998-07-08
NO317546B1 (no) 2004-11-15
HUT71208A (en) 1995-11-28

Similar Documents

Publication Publication Date Title
ATE156710T1 (de) Adjuvantien enthaltende impfstoffzusammensetzung
DE69126606D1 (de) Vakzine
NO934009D0 (no) Farmasoeytiske formuleringer
NO930699D0 (no) Hoeyeffektiv vaeske/vaeske hydrosyklon
KR900011476A (ko) 백신 제제
DK272889A (da) Vaccine
DE69027112D1 (de) Impfstoffzusammensetzung
FI944052L (fi) Oraalinen rokote
FI930577A0 (fi) Vaccin och behandlingsmetod foer hiv-infektion
FI933467L (fi) Komposition
DK189788D0 (da) Vaccine
FI925032L (fi) Vaccinsammansaettningar
DE69225104D1 (de) PCT-Zusammensetzung
ATE134386T1 (de) Vakzin-zusammensetzung
DE69225266D1 (de) Bis-bibenzimidazol Zusammensetzung
NO924484D0 (no) Pesticid sammensetning
FI925175A0 (fi) Kompositioner haerdbara medelst straolning
MX9202293A (es) Composicion de vacuna no-irritante.
NO943251D0 (no) Oral vaksine
ID1028B (id) Vaksin
NO923242D0 (no) Oral vaksine
BR1100918A (pt) Composição de vacina contendo adjuvantes
ITMI912766A1 (it) Composizione farmaceutica contenente n-acetil-cisteina
IE900354L (en) Vaccine composition

Legal Events

Date Code Title Description
MA Patent expired